ALRN-6924 vs RgIA

Head-to-head comparison of ALRN-6924 (ALRN-6924 dual MDM2/MDMX stapled p53 mimetic peptide) and RgIA (alpha-Conotoxin RgIA from Conus regius venom) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyALRN-6924RgIA
CategoryExperimentalExperimental
Full NameALRN-6924 dual MDM2/MDMX stapled p53 mimetic peptidealpha-Conotoxin RgIA from Conus regius venom
Molecular WeightN/A1,670 Da
Half-LifeHours to days depending on formulationMinutes to hours
Amino AcidsN/A13
Typical DoseVaries by clinical protocol10-300 pmol intrathecal|1-100 nM in vitro|single-dose rodent studies
RouteIntravenous/SubcutaneousIntrathecal
Purity≥98%≥98%
Studies Count40130
Research StatusClinicalPre-clinical

ALRN-6924 Benefits

  • p53 reactivation
  • dual MDM2/MDMX inhibition
  • protease resistance
  • tumor cell apoptosis

RgIA Benefits

  • alpha9alpha10 nAChR selectivity
  • neuropathic pain model tool
  • neuroimmune signaling research
  • analgesic lead discovery

ALRN-6924 Dosing

Clinical trial protocol dosing|Intermittent administration|Research-only escalation

RgIA Dosing

Intrathecal bolus in rodent pain models|Patch-clamp assays on alpha9alpha10 receptors|Single-dose pre-clinical screening

ALRN-6924 Side Effects

  • nausea
  • fatigue
  • myelosuppression

RgIA Side Effects

  • Transient autonomic effects
  • off-target nicotinic blockade
  • injection-site irritation

Research Overview

ALRN-6924

ALRN-6924 is one of the best-known stapled peptide therapeutics and has advanced into human oncology studies. Literature shows that hydrocarbon stapling can improve target affinity, serum stability, and cellular activity for this p53-mimetic scaffold.

RgIA

Scientific studies show RgIA can strongly inhibit alpha9alpha10 nicotinic signaling with high selectivity compared with many other nAChR ligands. It is widely used to probe peripheral sensory pathways and inflammation-linked pain mechanisms.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

ALRN-6924 stacks with:

venetoclaxcisplatindoxorubicin

RgIA stacks with:

gabapentinpregabalinduloxetine
stapled-peptidep53mdm2mdmxoncologycone-snailvenom-peptidenicotinic-receptorpain-research